title: Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome.
abstract: A 55-yr-old woman with a midgut carcinoid syndrome due to metastatic spread of an ileal tumor to the liver, paraortic and mediastinal lymph nodes and to the skeleton was given systemic radionuclide therapy with 111In-DTPA-D-Phe1-octreotide. Before therapy, dosimetric calculations were performed on whole-body scintigraphs and 111In retention was shown to be long-lasting. Excretion was mainly seen during the first 24 hr after injection; thereafter whole-body retention remained stationary at 30%. Indium-111 activity in tumor biopsies and blood was measured using a gamma counter. Very high tumor-to-blood ratios were obtained: 150 for the primary tumor and 400-650 for liver metastases, which further justified radiation therapy. Indium-111-DTPA-D-Phe1-octreotide treatment was given on three separate occasions (3.0, 3.5 and 3.1 GBq) 8 and 4 wk apart. After each therapy, the patient experienced facial flush and pain over the skeletal lesions followed by symptomatic relief, even though no objective tumor regression was found radiologically after 5 mo. After initiation of octreotide treatment, there was a 14% reduction of the main tumor marker, urinary 5-HIAA. After three subsequent radionuclide therapies, there was a further 31% reduction of 5-HIAA levels. No adverse reactions, other than a slight decrease in leukocyte counts, were seen. The mean absorbed radiation dose after the three treatments was estimated to be about 10-12 Gy in liver metastases and 3-6 Gy in other tumors, depending on the size and location of the metastases. Assuming internalization of 111In into tumor cells and a radiobiological effect from short range Auger and conversion electrons, there might be a therapeutic effect on the tumor.
authors.affiliation: Department of Nuclear Medicine, Sahlgrenska University Hospital, Göteborg, Sweden.
authors.forename: M
authors.initials: M
authors.lastname: Fjälling
authors.forename: P
authors.initials: P
authors.lastname: Andersson
authors.forename: E
authors.initials: E
authors.lastname: Forssell-Aronsson
authors.forename: J
authors.initials: J
authors.lastname: Grétarsdóttir
authors.forename: V
authors.initials: V
authors.lastname: Johansson
authors.forename: L E
authors.initials: LE
authors.lastname: Tisell
authors.forename: B
authors.initials: B
authors.lastname: Wängberg
authors.forename: O
authors.initials: O
authors.lastname: Nilsson
authors.forename: G
authors.initials: G
authors.lastname: Berg
authors.forename: A
authors.initials: A
authors.lastname: Michanek
authors.forename: G
authors.initials: G
authors.lastname: Lindstedt
authors.forename: H
authors.initials: H
authors.lastname: Ahlman
mesh_terms: D005260:Female; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000652:urine; D007205:Indium Radioisotopes / Q000627:therapeutic use*; D008303:Malignant Carcinoid Syndrome / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D008875:Middle Aged; D015282:Octreotide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004369:Pentetic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011877:Radionuclide Imaging; D011879:Radiotherapy Dosage; D014057:Tomography, X-Ray Computed
chemical_list: D007205:Indium Radioisotopes; C071632:SDZ 215-811; D006897:Hydroxyindoleacetic Acid; D004369:Pentetic Acid; D015282:Octreotide